DEFINITIVE PROXY STATEMENT

Company

Actinium Pharmaceuticals, Inc.

Filed

November 25, 2019

Period of Report

December 18, 2019

Accession Number

0001213900-19-024628

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →